Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology

Berlin / Boston, June 29, 2022 – Bayer AG launched this day the outlet of its fresh Learn and Innovation Heart at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding additional the firm’s footprint into surely one of the sector’s most modern pharmaceutical learn and pattern locations. Representing a complete $140M USD investment into the put, Bayer’s 62,100-sq.-foot constructing homes a brand fresh center of precision molecular oncology learn geared up with snort-of-the-art laboratories and locations of work for the pattern of fresh centered most cancers therapies for patients. Moreover, the center comprises a newly established learn crew centered on leveraging chemical biology tactics to additional propel the firm’s oncology drug pattern process. 

“Our fresh Bayer learn and innovation center at Kendall Square is piece of our intention to be on the forefront of scientific discovery and leap forward innovation for better affected person healthcare,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “Being piece of this outlandish innovation ecosystem will toughen our teams in constructing leap forward improvements for patients alongside with the consultants here.”

“Bayer has a rising crew of world-class innovators – from our internal consultants and companions a lot like Vividion, to our global community of academic and enterprise companions, quite hundreds of that would be found neutral appropriate here within the Boston put,” said Christian Rommel, Member of the Govt Committee of Bayer AG’s Pharmaceutical Division and Head of Learn and Vogue at Bayer. “Our fresh learn and innovation center in Kendall Square brings us closer to those companions, to fellow scientists and institutions that join us in our mission to care for up pushing the boundaries of clinical innovation with the aim of bringing impactful well being solutions to patients.” 

“Now we bear introduced a assortment of outlandish oncology treatments to patients all by the final years,” said Christine Roth, Member of the Govt Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU at Bayer. “Our ambition is to play a prime role within the next wave of leap forward improvements in oncology. The outlet of our fresh learn center at Kendall Square with its dedicated learn crew of precision oncology consultants demonstrates our dedication to investing within the next wave of innovation that has the aptitude to impress the way in which most cancers is treated.”

“At Kendall Square, we discover the innovation-driven businesses, entrepreneurship, world-class academics, cutting-edge learn, leap forward applied sciences, infrastructure, and culture to toughen our strategic targets,” said Marianne De Backer, MBA, Ph.D., Member of the Govt Committee of the Pharmaceuticals Division and Head of Procedure, Business Vogue & Licensing and Originate Innovation at Bayer. “It helps us to additional solidify our presence and dedication on this brilliant and rising ecosystem that affords us a chance to connect with latest and future pioneers within the pharmaceutical sector. We’re here to study long-lasting relationships that can slump our quest for fresh treatments and applied sciences. Together, we are in a position to leverage our cumulative expertise and property, and indubitably transform affected person lives.”

Spanning across two floors, the fresh center within the imply time affords put for 100 workers, while the firm is able to make a decision on up an additional 50 roles within the upcoming months. It’s designed to enhance the collaboration between Bayer learn and pattern, its internal companions a lot like BlueRock Therapeutics, Asklepios BioPharmaceutical (AskBio) and Vividion Therapeutics, in addition as external companions to slump the pattern of transformative treatments for patients. Moreover to the fresh center at Kendall Square in Cambridge, Bayer has furthermore established strategic learn collaborations with top scientific companions in Boston, including joint laboratories within the areas of lung illness with Brigham and Females’s Health center and Massachusetts Smartly-liked Health center and precision cardiology with the Enormous Institute of MIT and Harvard.

The Learn and Innovation Heart furthermore marks a strategic investment into Bayer’s oncology innovation to transform healthcare for people residing with most cancers worldwide, and on the identical time to study particular sustainable long-time duration advise for the firm. Striving to change into a top 10 oncology firm by 2030, Bayer is investing a prime fragment of its global R&D budget in opposition to oncology. The fresh precision molecular oncology learn center will force the pattern of centered subsequent-know-how most cancers therapies, including efforts to wait on people residing with most cancers bear the help of molecular assessments and centered treatments by biomarker attempting out.

Bayer has a 160-year tune file of handing over scientific innovation for patients in areas of high clinical need and has long embraced external innovation and partnering. Since 2020, Bayer has secured bigger than 40 transactions in enterprise pattern and licensing and invested $1.5B USD in partnerships by its Leaps by Bayer impact investments, and the fresh center is anticipated to play a job for future partnering investments and collaborations.

With this fresh center, Bayer is expanding its operations within the main life sciences cluster worldwide. Boston-Cambridge is dwelling to approximately 1,000 biotechnology firms, with Kendall Square being the center of pharmaceutical innovation on the East Float of the United States. The firm is now mark in four of the supreme biotechnology hubs within the US – Boston, San Francisco, San Diego and Learn Triangle Park, NC.